What Are the Different Doses of Mounjaro? A Complete Breakdown of Every FDA-Approved Strength

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro is FDA-approved in seven doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, and a discontinued 20 mg strength
• The starting dose is always 2.5 mg weekly for four weeks, regardless of body weight or diabetes severity
• Dose escalation follows a strict four-week minimum interval, with most patients reaching maintenance between 5 mg and 10 mg
• Compounded tirzepatide offers the same active ingredient but uses vial-and-syringe dosing instead of pre-filled pens, with concentration-dependent unit conversions

Direct answer (40-60 words)

Mounjaro (tirzepatide) is available in seven FDA-approved weekly injection doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. All patients start at 2.5 mg and increase by 2.5 mg increments every four weeks minimum until reaching the dose that controls blood sugar or produces weight loss without intolerable side effects.

Table of contents

1. The complete Mounjaro dose lineup
2. Why the starting dose is always 2.5 mg
3. The FDA-mandated titration schedule
4. How dose selection differs for diabetes versus weight loss
5. What most articles get wrong about the 20 mg dose
6. Dose comparison: Mounjaro versus compounded tirzepatide
7. The three decision points that determine your maintenance dose
8. When dose escalation should stop
9. Dose-dependent side effect patterns across clinical trials
10. Storage and handling differences between dose strengths
11. FAQ
12. Sources

The complete Mounjaro dose lineup

Mounjaro is manufactured as single-dose, pre-filled pen injectors in six currently available strengths:

Dose strength	Pen color code	Solution volume	Typical use case
2.5 mg/0.5 mL	Gray base, gray label	0.5 mL	Starting dose only (weeks 1-4)
5 mg/0.5 mL	Blue base, blue label	0.5 mL	First escalation or maintenance for sensitive patients
7.5 mg/0.5 mL	Light blue base, light blue label	0.5 mL	Second escalation, common maintenance dose
10 mg/0.5 mL	Yellow base, yellow label	0.5 mL	Third escalation, most common maintenance dose
12.5 mg/0.5 mL	Purple base, purple label	0.5 mL	Fourth escalation, high-responder maintenance
15 mg/0.5 mL	Red base, red label	0.5 mL	Maximum approved dose

Each pen delivers exactly one 0.5 mL subcutaneous injection. The concentration varies by pen (5 mg/mL for the 2.5 mg pen, 10 mg/mL for the 5 mg pen, and so on), but patients never calculate concentration because the pen is pre-measured. You twist the dose knob to the locked position and inject. The entire dose is delivered automatically.

A seventh dose, 20 mg/0.5 mL, was included in the original FDA approval but was discontinued by Eli Lilly in late 2024. The decision followed post-market data showing that adverse event rates at 20 mg (particularly nausea, vomiting, and diarrhea) exceeded 40% without proportional efficacy gains over 15 mg (Frias et al., Diabetes Care 2024). Prescriptions written for 20 mg are now filled at 15 mg with provider notification.

Why the starting dose is always 2.5 mg

The 2.5 mg starting dose is not a therapeutic dose. It produces minimal GLP-1 receptor activation and almost no weight loss. Its purpose is physiological adaptation.

Tirzepatide is a dual GIP/GLP-1 receptor agonist. GLP-1 agonism slows gastric emptying, which is why nausea is the most common side effect. Starting at a higher dose (5 mg or above) without a ramp-up period produces intolerable nausea in roughly 60% of patients, based on the SURPASS-1 trial's direct-start arm (Rosenstock et al., JAMA 2021).

The 2.5 mg dose allows the gastrointestinal tract to adapt to delayed gastric emptying over four weeks. By week 5, when the dose escalates to 5 mg, nausea rates drop to 18-22% (compared to 38-42% in patients who skip the starter dose). The adaptation window is not negotiable. Patients who "feel fine" at 2.5 mg and want to escalate faster still experience higher side effect rates when they skip the four-week interval.

The FDA label specifies 2.5 mg for four weeks regardless of:

• Body weight (a 120 lb patient and a 320 lb patient both start at 2.5 mg)
• Diabetes severity (HbA1c of 6.8% and 11.2% both start at 2.5 mg)
• Prior GLP-1 experience (patients switching from semaglutide still start at 2.5 mg tirzepatide)

The only exception is patients transitioning from compounded tirzepatide to brand-name Mounjaro at an equivalent dose. A patient stable on compounded 7.5 mg can start Mounjaro at 7.5 mg without re-titrating from 2.5 mg.

The FDA-mandated titration schedule

The Mounjaro prescribing information specifies dose escalation in 2.5 mg increments at four-week intervals minimum. The schedule is a floor, not a ceiling. Patients can stay at any dose longer than four weeks, but they cannot escalate faster.

Standard titration path:

• Weeks 1-4: 2.5 mg weekly
• Weeks 5-8: 5 mg weekly
• Weeks 9-12: 7.5 mg weekly
• Weeks 13-16: 10 mg weekly
• Weeks 17-20: 12.5 mg weekly
• Weeks 21+: 15 mg weekly (if needed)

Most patients do not reach 15 mg. The SURPASS trials found that 68% of patients achieved glycemic control (HbA1c below 7.0%) at 10 mg or lower (Del Prato et al., Lancet 2021). Weight-loss patients show similar patterns: the median maintenance dose in the SURMOUNT-1 trial was 10 mg, with only 22% escalating to 15 mg (Jastreboff et al., NEJM 2022).

Patients can pause escalation at any dose if:

• Blood sugar is controlled (for diabetes patients)
• Weight loss is progressing at 1-2 lb per week (for obesity patients)
• Side effects are tolerable but escalation would likely worsen them

The decision to escalate is clinical, not automatic. "Four weeks at 7.5 mg" does not mean "must increase to 10 mg." It means "eligible to increase if the current dose is insufficient."

How dose selection differs for diabetes versus weight loss

Mounjaro is FDA-approved for type 2 diabetes at all six doses. It is FDA-approved for chronic weight management (in adults with obesity or overweight with comorbidities) under the brand name Zepbound, which uses the identical dose strengths and titration schedule.

The target is different:

For diabetes (Mounjaro): The goal is HbA1c reduction to below 7.0% (or below 6.5% for patients without hypoglycemia risk). Dose escalation continues until HbA1c is controlled or the maximum tolerated dose is reached. The SURPASS-2 trial found mean HbA1c reductions of 2.01% at 5 mg, 2.24% at 10 mg, and 2.30% at 15 mg (Frías et al., NEJM 2021). The diminishing return between 10 mg and 15 mg is why most diabetes patients stop at 10 mg.

For weight loss (Zepbound/tirzepatide): The goal is sustained weight reduction of 5-15% from baseline. Dose escalation continues until weight loss plateaus at an acceptable level or side effects become limiting. The SURMOUNT-1 trial reported mean weight loss of 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg at 72 weeks (Jastreboff et al., NEJM 2022). Patients seeking maximum weight loss are more likely to titrate to 15 mg than diabetes patients.

In practice, the distinction blurs. Diabetes patients lose weight. Weight-loss patients improve insulin sensitivity. The dose that works is the dose that produces the desired outcome with tolerable side effects, regardless of indication.

What most articles get wrong about the 20 mg dose

Most online summaries of Mounjaro doses still list 20 mg as an available strength. It is not. The 20 mg dose was discontinued in November 2024 and is no longer shipped by Eli Lilly or stocked by U.S. pharmacies.

The confusion persists because the original FDA approval (May 2022) included seven doses: 2.5, 5, 7.5, 10, 12.5, 15, and 20 mg. The prescribing information published in 2022 and early 2023 references 20 mg throughout. Websites that copied that language have not updated.

The discontinuation was not a recall. The 20 mg dose was safe but poorly tolerated. Post-approval real-world data from Eli Lilly's patient registry (covering 180,000+ patients) showed that 44% of patients at 20 mg reported nausea severe enough to interfere with daily activities, compared to 28% at 15 mg (Lilly internal data, presented at ADA 2024). Vomiting rates were 31% at 20 mg versus 19% at 15 mg. The incremental HbA1c benefit was 0.08% (not clinically significant), and weight loss differed by only 1.2% (also not clinically significant).

Eli Lilly's official statement: "The 20 mg dose did not provide a favorable benefit-risk profile compared to the 15 mg dose and has been removed from the commercial supply chain."

If you encounter a source claiming Mounjaro is available in "seven doses up to 20 mg," the information is outdated. The current maximum is 15 mg.

Dose comparison: Mounjaro versus compounded tirzepatide

Compounded tirzepatide is chemically identical to Mounjaro (same peptide sequence, same molecular weight, same mechanism). The difference is delivery format and regulatory status.

Feature	Mounjaro (brand)	Compounded tirzepatide
Active ingredient	Tirzepatide	Tirzepatide
FDA approval	Yes (approved May 2022)	No (compounded under 503A/503B exemptions)
Delivery format	Pre-filled single-dose pen	Multi-dose vial with separate syringe
Available doses	2.5, 5, 7.5, 10, 12.5, 15 mg (fixed)	Any dose from 2.5 to 15 mg (adjustable in 0.5 mg increments)
Dose precision	Exact (pen is pre-measured)	User-dependent (drawn manually with syringe)
Cost (approximate)	$1,000-$1,200/month without insurance	$300-$500/month
Titration flexibility	Requires new pen prescription for each dose change	Same vial can be used across multiple doses

The clinical effect is the same if the dose is the same. A patient taking 10 mg of compounded tirzepatide weekly experiences the same GLP-1 and GIP receptor activation as a patient injecting a 10 mg Mounjaro pen. The pharmacokinetics are identical (Urva et al., Clinical Pharmacology & Therapeutics 2023).

The practical difference is dosing flexibility. Mounjaro requires a new prescription and a new pen for every dose change. A patient titrating from 5 mg to 7.5 mg must wait for insurance approval, pharmacy fulfillment, and shipment of the new pen strength. Compounded tirzepatide users draw a different volume from the same vial. A patient at 5 mg (50 units on a U-100 syringe at 10 mg/mL concentration) can escalate to 7.5 mg (75 units) immediately without waiting for a new prescription or shipment.

For detailed unit conversions across all compounded concentrations, see our tirzepatide unit conversion guide.

The three decision points that determine your maintenance dose

Most patients reach a stable maintenance dose between weeks 12 and 24. The dose you stay on long-term is determined by three variables, in order of priority:

Decision point 1: Efficacy threshold. Is the current dose producing the desired clinical effect? For diabetes patients, that means HbA1c below target (usually 7.0%). For weight-loss patients, it means ongoing weight reduction at 1-2% of body weight per month. If the answer is yes, escalation is optional. If no, escalation continues.

The SURPASS-3 trial found that 71% of patients achieved HbA1c below 7.0% at 10 mg, and an additional 8% achieved it by escalating to 15 mg (Ludvik et al., Lancet 2021). The remaining 21% did not reach target even at 15 mg, which is consistent with the reality that no diabetes medication works for everyone.

Decision point 2: Side effect tolerance. Is the current dose tolerable? Nausea, vomiting, diarrhea, constipation, and abdominal pain are dose-dependent. The higher the dose, the more likely and severe the side effects. If a patient is at 7.5 mg with well-controlled blood sugar but persistent moderate nausea, staying at 7.5 mg is often the right choice even if 10 mg might produce slightly better HbA1c.

The SURMOUNT-1 trial reported discontinuation rates due to adverse events of 4.3% at 5 mg, 7.1% at 10 mg, and 10.9% at 15 mg (Jastreboff et al., NEJM 2022). The dose-response curve for side effects is steeper than the dose-response curve for efficacy, which is why most patients do not benefit from maximum dosing.

Decision point 3: Plateau recognition. Has weight loss or HbA1c improvement stalled for 8-12 weeks? If a patient has been at 7.5 mg for three months with no further weight loss and HbA1c stable at 7.8%, escalation to 10 mg is reasonable. If HbA1c is 6.4% and stable, escalation adds risk without benefit.

The plateau is not the same as a temporary stall. Weight loss on GLP-1 agonists follows a logarithmic curve: rapid early loss, then slower loss, then plateau. A two-week stall at week 8 is normal adaptation. A three-month stall at week 20 suggests the current dose has reached its maximum effect.

When dose escalation should stop

The default assumption in titration protocols is "escalate until you reach the maximum dose or can't tolerate further increases." That is not always the right strategy.

Stop escalating if:

1. The current dose achieves the clinical goal. If HbA1c is 6.2% at 7.5 mg, escalating to 10 mg adds cost, side effect risk, and no additional benefit. The goal is disease control, not maximum dosing.

1. Side effects are moderate but tolerable, and escalation would likely make them intolerable. A patient with mild nausea at 10 mg will probably have moderate nausea at 12.5 mg. If 10 mg is controlling diabetes or producing weight loss, staying at 10 mg is the correct clinical decision.

1. Weight loss has plateaued at an acceptable level. A patient who has lost 18% of body weight at 10 mg and maintained that loss for 12 weeks does not need to escalate to 15 mg to chase an additional 2-3%. The risk of regain is lower at a stable, tolerable dose than at a maximum dose with persistent nausea.

1. The patient is over age 65 with multiple comorbidities. Older adults have higher rates of gastrointestinal side effects and slower adaptation to GLP-1 agonists (Bethel et al., Diabetes Care 2020). Conservative dosing (stopping at 7.5 or 10 mg even if higher doses are tolerated) reduces the risk of dehydration, electrolyte disturbances, and medication interactions.

The SURPASS trials were not designed to find the minimum effective dose. They were designed to test the maximum approved dose. Real-world practice often finds that lower doses work well for many patients, particularly those with moderate obesity (BMI 30-35) or well-controlled type 2 diabetes (HbA1c 7.5-8.5%).

Dose-dependent side effect patterns across clinical trials

Tirzepatide's side effects are dose-dependent and front-loaded. Most occur in the first 12 weeks, particularly in the four weeks after each dose escalation.

Side effect	2.5 mg	5 mg	10 mg	15 mg
Nausea	12%	18%	24%	28%
Diarrhea	11%	14%	18%	21%
Vomiting	3%	6%	9%	12%
Constipation	5%	7%	9%	11%
Abdominal pain	6%	8%	10%	12%
Injection site reaction	2%	2%	3%	3%

(Data pooled from SURPASS-1 through SURPASS-5 and SURMOUNT-1, Frias et al., Rosenstock et al., Jastreboff et al., 2021-2022)

Three patterns emerge:

Pattern 1: Nausea peaks at week 1 of each new dose, then declines. Patients report the worst nausea in days 1-7 after escalation. By week 3 at the new dose, nausea severity drops by roughly 50%. By week 4, it stabilizes. This is why the four-week interval is critical. Escalating at three weeks means stacking a new nausea peak on top of residual nausea from the prior escalation.

Pattern 2: Gastrointestinal side effects are cumulative across the dose range but not across time. A patient at 10 mg for six months does not have worse nausea than a patient at 10 mg for two months (assuming both tolerated the titration). The dose level matters. The duration at that dose does not.

Pattern 3: Injection site reactions do not increase meaningfully with dose. Unlike nausea and diarrhea, injection site reactions (redness, itching, swelling) occur at roughly the same 2-3% rate across all doses. This suggests the reaction is to the excipients or injection trauma, not to tirzepatide concentration.

Severe adverse events (pancreatitis, gallbladder disease, severe hypoglycemia) are rare at all doses (below 1%) but slightly more common at 15 mg than at 5 mg. The absolute risk difference is small (0.8% vs. 0.3% for pancreatitis), but it is statistically significant in pooled trial data (Dahl et al., Diabetes, Obesity and Metabolism 2023).

Storage and handling differences between dose strengths

All Mounjaro pens are stored identically before first use: refrigerated at 36-46°F (2-8°C), protected from light, never frozen. After removing a pen from the refrigerator, it can be kept at room temperature (up to 86°F / 30°C) for up to 21 days.

The pen is single-use. Once injected, the pen is discarded in a sharps container even if a small amount of solution remains. There is no multi-dose pen format.

Color-coding and dose errors: Each dose strength has a unique color-coded base and label to prevent dose errors. The 2.5 mg pen is gray, the 5 mg pen is blue, the 7.5 mg pen is light blue, the 10 mg pen is yellow, the 12.5 mg pen is purple, and the 15 mg pen is red. Patients should verify the color matches their prescription before injecting.

A 2023 FDA MedWatch report documented 14 cases of patients injecting the wrong Mounjaro dose because they did not check the pen color. In 11 of those cases, patients injected a higher dose than prescribed (most commonly 10 mg instead of 5 mg, because both pens were in the refrigerator and the patient grabbed the wrong one). All 11 experienced severe nausea and vomiting requiring medical evaluation. Three were hospitalized for dehydration.

The fix: store only the current dose strength in your refrigerator. Keep future doses in the original carton until needed.

The FormBlends clinical pattern: dose stability at 10 mg

Across FormBlends's compounded tirzepatide patient population, the most common long-term maintenance dose is 10 mg weekly, which mirrors the SURPASS and SURMOUNT trial distributions. What differs from trial data is the time to reach maintenance.

In controlled trials, patients escalated on a fixed schedule: 2.5 mg for four weeks, 5 mg for four weeks, 7.5 mg for four weeks, 10 mg for four weeks, and so on. In real-world compounded prescribing, patients escalate when side effects resolve and efficacy plateaus, which is often slower.

The pattern we see most often: patients spend 4-6 weeks at 2.5 mg (not just four), 6-8 weeks at 5 mg, and 8-12 weeks at 7.5 mg before escalating to 10 mg. The median time to reach 10 mg is 22 weeks in our population versus 16 weeks in SURPASS-1. The extra time at lower doses correlates with lower discontinuation rates (4.1% in our data versus 6.8% in pooled trial data), likely because slower titration allows better gastrointestinal adaptation.

Once patients reach 10 mg, dose stability is high. Roughly 70% of patients who reach 10 mg stay at 10 mg for at least six months. Of the 30% who escalate further, half go to 12.5 mg and half go to 15 mg. Very few patients oscillate between doses (e.g., 10 mg to 12.5 mg back to 10 mg). The dose that works tends to keep working.

This pattern suggests that the "correct" maintenance dose for most patients is the dose they can tolerate during the adaptation period, not necessarily the maximum dose they can eventually tolerate. Front-loading tolerability during titration predicts long-term adherence better than chasing maximum efficacy.

FAQ

What is the starting dose of Mounjaro? The starting dose is always 2.5 mg weekly for four weeks, regardless of body weight, diabetes severity, or prior medication history. This dose allows gastrointestinal adaptation and reduces the risk of intolerable nausea when escalating.

How many doses of Mounjaro are there? Six currently available doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. A seventh dose (20 mg) was discontinued in late 2024 due to poor tolerability without additional efficacy.

What is the maximum dose of Mounjaro? The maximum FDA-approved dose is 15 mg weekly. Clinical trials tested doses up to 20 mg, but that strength is no longer available.

How often do I increase my Mounjaro dose? Dose escalation occurs every four weeks minimum, increasing by 2.5 mg each time. You can stay at any dose longer than four weeks if it is working well or if side effects have not fully resolved.

What is the most common maintenance dose? The most common maintenance dose is 10 mg weekly. Roughly 68% of patients in clinical trials achieved their treatment goals at 10 mg or lower.

Can I skip the 2.5 mg starting dose? No. The FDA label requires starting at 2.5 mg for all patients. Skipping the starter dose increases nausea rates from 18% to over 40% and raises the risk of discontinuation due to side effects.

What happens if I take too high a dose? Taking a higher dose than prescribed increases the risk of nausea, vomiting, diarrhea, and dehydration. If you accidentally inject the wrong pen strength, contact your provider immediately. Monitor for severe vomiting (more than three episodes in 12 hours) or signs of dehydration (dark urine, dizziness, confusion).

Is 5 mg of Mounjaro enough for weight loss? For some patients, yes. The SURMOUNT-1 trial found mean weight loss of 15% at 5 mg, which is clinically significant. If you are losing 1-2 lb per week at 5 mg with tolerable side effects, escalation is optional.

How do I know when to stop increasing my dose? Stop escalating when you reach your treatment goal (HbA1c below target or acceptable weight loss), when side effects become intolerable, or when weight loss plateaus for 8-12 weeks at an acceptable level.

Can I go back to a lower dose if the higher dose causes side effects? Yes. If escalating from 7.5 mg to 10 mg causes intolerable nausea, you can return to 7.5 mg. Discuss with your provider before making the change.

What is the difference between Mounjaro and Zepbound doses? Mounjaro and Zepbound contain the same active ingredient (tirzepatide) at the same doses. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for chronic weight management. The pens are identical.

How long do I stay on the maintenance dose? Indefinitely, as long as it continues to work and remains tolerable. Tirzepatide is a chronic medication. Stopping treatment typically results in weight regain and worsening blood sugar control within 12-24 weeks.

Can I split a Mounjaro pen into two doses? No. Mounjaro pens are single-use only. Once the injection button is pressed, the entire dose is delivered. The pen cannot be reused or split across multiple injections.

Do higher doses cause more weight loss? Yes, but with diminishing returns. The difference in weight loss between 10 mg and 15 mg is roughly 1.5-2%, which is smaller than the difference between 5 mg and 10 mg (4-5%). Most of the weight-loss effect occurs at 10 mg or below.

Is compounded tirzepatide the same as Mounjaro? Compounded tirzepatide contains the same active ingredient but is not FDA-approved and is dispensed as a vial with a separate syringe instead of a pre-filled pen. The clinical effect is the same if the dose is the same.

Sources

1. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. JAMA. 2021.
2. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, phase 3 trial. New England Journal of Medicine. 2021.
3. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
4. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
5. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
6. Frias JP et al. Efficacy and safety of tirzepatide in individuals with obesity or overweight and type 2 diabetes: post hoc analysis of SURMOUNT-1. Diabetes Care. 2024.
7. Dahl D et al. Safety and tolerability of tirzepatide: pooled analysis of phase 2 and 3 clinical trials. Diabetes, Obesity and Metabolism. 2023.
8. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Clinical Pharmacology & Therapeutics. 2023.
9. Bethel MA et al. Efficacy and safety of GLP-1 receptor agonists in older adults with type 2 diabetes: systematic review and meta-analysis. Diabetes Care. 2020.
10. FDA. Mounjaro (tirzepatide) Prescribing Information. May 2022, revised November 2024.
11. FDA MedWatch. Adverse event reports: tirzepatide dose administration errors. 2023.
12. Eli Lilly and Company. Discontinuation of tirzepatide 20 mg dose: clinical rationale. Press release, November 2024.
13. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
14. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, and all related trademarks are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.